The researchers designed this retrospective cohort study to examine the effect of demographics, including race/ethnicity, insurance status, age, and geographic location, on prostate cancer screening ...

Investigators conducted a cross-sectional survey to identify factors associated with psychological hardship related to the ...

Lung transplantation can prolong survival for select patients with medically refractory, lung-limited, stage IV non-small cell lung cancer (NSCLC), according to a study published online July 8 in the ...

Investigators conducted this cross-sectional secondary analysis using baseline data from a phase 3 randomized controlled trial to explore associations between fear of cancer recurrence and coping ...

In this systematic review, researchers aimed to analyze the uptake of breast cancer risk management strategies, including prophylactic mastectomy, intensive surveillance, or no active strategy, in ...

FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.

The odds of human papillomavirus (HPV)-related cancers are increased among people with HIV (PWH) and solid organ transplant recipients (SOTRs), according to a study published online June 30 in JAMA ...

Rates of prostate cancer screening shared decision-making (SDM) are very low in family medicine practices, according to a study published in the June issue of the Southern Medical Journal. Nicholas ...

Investigators compared the safety and efficacy of polatuzumab vedotin with or without rituximab, gemcitabine, and oxaliplatin in first line for patients with relapsed/refractory diffuse large B-cell ...

A quality improvement study analyzed the value of advanced telehealth delivery methods during prostate cancer management.

More adverse events of grade 3 or higher reported for participants receiving pembrolizumab-belzutifan than pembrolizumab-placebo ...

Using individual patient data from phase 2 and 3 trials, investigators analyzed the value of pathologic complete response vs ctDNA clearance after neoadjuvant immunotherapy or perioperative ...